Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1584-1587, 2023.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-1010010
Biblioteca responsável:
WPRO
ABSTRACT
Multiple myeloma (MM) is a common plasma cell malignancy, accounting for the second largest hematological malignancy. Proteasome inhibitors represented by bortezomib (BTZ) have been the main treatment for patients with newly diagnosed and relapsed or refractory myeloma in nearly two decades. Although BTZ has improved the prognosis of MM patients, MM remains incurable in most patients, mainly because MM cells become resistant to BTZ. This review is to better understand the mechanism of MM resistance to BTZ and explore possible new therapeutic strategies.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plasmócitos
/
Prognóstico
/
Resistencia a Medicamentos Antineoplásicos
/
Linhagem Celular Tumoral
/
Inibidores de Proteassoma
/
Bortezomib
/
Mieloma Múltiplo
/
Antineoplásicos
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2023
Tipo de documento:
Artigo